跳至主要内容
临床试验/NCT07108933
NCT07108933已完成2 期

Effect of Scheduled Autologous Platelet-rich Plasma Guided Injection in the Healing Process of Critical-sized Maxillary Bony Defects After Surgical Excision of Non- Malignant Lesions: A Prospective Randomized Clinical Trial.

Horus University1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2023年8月15日最近更新:
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
16
试验地点
1
主要终点
Volume of the injected bony defect

研究概览

简要总结

Scheduled autologous platelet-rich plasma guided injection is done in critical-sized maxillary bony defects after surgical excision of non- malignant lesions.

详细描述

The study aims to detect the effect of scheduled autologous platelet-rich plasma- guided injection in the healing process of critical-sized maxillary bony defects after surgical removal of non-malignant lesions by using bone volumetric analysis and density measuring with cone beam computed tomography.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

No masking

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18-65 years (adults within a specific age range).
  • Diagnosis: Non-malignant maxillary bony defects (e.g., benign tumors or cysts).
  • Health: Generally healthy participants who can tolerate surgery.
  • Platelet Function: No platelet disorders or blood-related conditions.
  • Willingness: Informed consent and ability to follow the protocol.
  • No Use of Blood Thinners: No current use of anticoagulants like aspirin.

排除标准

  • Age: Children (under 18) and elderly (over 75).
  • Malignant Lesions: Participants with cancer or pre-cancerous conditions.
  • Systemic Illness: Severe conditions (e.g., uncontrolled diabetes, autoimmune disorders).
  • Platelet Disorders: Low platelet count or bleeding disorders (e.g., hemophilia).
  • Infections: Active infections or inflammatory conditions (e.g., periodontal disease).
  • Pregnancy: Women who are pregnant or breastfeeding.
  • Recent Surgery/Trauma: Recent maxillary surgery or trauma.
  • Uncontrolled Medications: Use of blood thinners, NSAIDs, or immunosuppressive drugs.
  • Non-compliance: Unwillingness or inability to follow-up with the protocol.
  • Substance Abuse: Active drug or alcohol abuse.

研究组 & 干预措施

Injection

Other

Scheduled injection of autologous platelet-rich plasma

干预措施: Autologous platelet-rich plasma (Biological)

结局指标

主要结局

Volume of the injected bony defect

时间窗: after 3 months

the volume of the injected bony defect is measured by Cone beam computed tomography in millimeters cubic.

次要结局

  • Bone density at the injected site(after 3 months)

研究者

发起方
Horus University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eman Abdel Salam Yousef

Associate professor

Horus University

研究点 (1)

Loading locations...

相似试验